Eckert & Ziegler: Record Income and Sales in 2015; Strong Rise in Net Liquidity. Hasselmann joins BEBIG Management Board

(Ad hoc press release)

Berlin, March 21, 2016, 19:31 CET – Eckert & Ziegler AG, a specialist for isotope-based applications in medicine, science and industry, finished fiscal year 2015 with new records in terms of income and sales. As the Supervisory Board stated at its balance sheet meeting on Monday, net profit for the year was € 10.7 million, or € 2.03 per share – the best result since the company’s founding. Sales exceeded € 140 million. Net liquidity, the amount by which cash and cash equivalents exceeded liabilities, grew as of December 31, 2015 by € 12.8 million to € 15.9 million, reaching the highest value since 2012. 

At the Annual General Meeting on June 8, 2016, the Executive Board and the Supervisory Board will propose a dividend of € 0.60 per share entitled to a dividend (prior year: € 0.60). 

Additional text:
In terms of content, the annual financial statements were influenced by a series of one-off effects. Extraordinary income from the sale of an investment was offset by losses in the Radiation Therapy segment and an increase in risk provisioning. With regard to sales and income, the Group also benefited from the lower external value of the euro. The detailed figures will be published on March 23, 2016.

As part of the reorganization of the Radiation Therapy segment, plans are in place to transfer Dr. Edgar Löffler’s position as Executive Director on the Board of Directors of Eckert & Ziegler BEBIG s.a. to Dr. Harald Hasselmann at mid-year. Dr. Löffler will remain a member of the Executive Board of Eckert & Ziegler AG, where he will continue to be responsible for the Radiation Therapy segment.

For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10,
13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138
karolin.riehle@dont-want-spam.ezag.de, www.ezag.de